Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07347249 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

StatusRecruiting
PhasePhase 2
SponsorHemab ApS
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later Jul 2026 → Nov 2027
See other at-risk trials from Hemab ApS

Record History

  1. Primary and study completion pushed from Jul 2026 to Nov 2027v4
  2. Start date changed from estimate of Jan 2026 to Mar 11, 2026v3
  3. Site contact updatedv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hemab ApS
5 trials monitored
See 1 trial at risk
Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of sutacimig monotherapy in participants with congenital FVII deficiency (FVIID).
Trial Details
NCT Number NCT07347249
Lead Sponsor Hemab ApS
Conditions
(from sponsor)		 Congenital Factor VII Deficiency
Related terms Factor VII Deficiency
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov